

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement



Kindstar Globalgene Technology, Inc.

康聖環球基因技術有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock code: 9960)

VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY DIRECTOR

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company was informed by Dr. Huang Shiang (“**Dr. Huang**”), the Chairman, Chief Executive Officer, Chief Medical Officer and an executive Director of the Company, that during the period from May 24, 2022 to May 27, 2022, Dr. Huang has increased his shareholding in the Company by purchasing 148,500 shares of the Company on the open market at an average price of HK\$2.25 per share for a total consideration of approximately HK\$334,175 (excluding related transaction fees) (the “**Increase in Shareholding**”).

Immediately after the Increase in Shareholding, by virtue of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), Dr. Huang is interested in or deemed to be interested in 145,818,368 shares in the Company, representing approximately 14.67% of the issued share capital of the Company as at the date of this announcement. Dr. Huang has expressed his confidence in the overall development prospects and the potential growth of the Company. Dr. Huang will further increase his shareholding in the Company in the future as and when appropriate, subject to compliance with applicable legal and regulatory requirements.

According to the information available to the Company and to the best knowledge of the Board, the Company has maintained sufficient public float of the issued shares after the Increase in Shareholding and as at the date of this announcement.

By order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, May 30, 2022

As of the date of this announcement, the Board comprises Dr. Huang Shiang, Mr. Tu Zanbing and Ms. Chai Haijie as executive Directors, Mr. Huang Zuie-Chin, Mr. Peng Wei and Ms. Huang Lu as non-executive Directors, and Dr. Yao Shanglong, Dr. Xia Xinping and Mr. Gu Huaming as independent non-executive Directors.